Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity
British Journal of Radiology · 2025
DOI: 10.1093/bjr/tqaf034 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Radiology, 2025. Verfasst von Ruxi Chang und 4 weiteren Autor:innen. Beteiligte Einrichtung: PET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Fluorodeoxyglucose F18, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National High Performance medical Device Innovation Center Innovation Fund.
Abstract (Originalsprache)
Objectives
The purpose of this study is to evaluate the effectiveness of using 18F-FDG PET/CT metabolic heterogeneity to assess the programmed cell death ligand (PD-L1) expression in primary tumours.
Methods
Data from 103 non-small cell lung cancer (NSCLC) patients undergoing 18F-FDG PET/CT were collected. PD-L1 expression was verified via biopsy or surgical specimens. The coefficient of variation (COV) assessed metabolic heterogeneity of the primary tumour. ROC curves evaluated the predictive potential of metabolic metrics and defined thresholds. Logistic regression examined predictors of PD-L1 expression.
Results
The study included 103 patients (mean age: 63.65 ± 9.28 years), of whom 60 were male. Sixty-four patients had positive PD-L1 expression, while 39 had negative PD-L1 expression. COV was significantly higher in the PD-L1-positive group (Z = −2.529, P = 0.011), while no significant differences were noted in other parameters between the groups (P > 0.05 for all). The optimal cut-off value was proposed as 28.9, with sensitivity and specificity of 46.9% (34.3%-59.8%) and 82.1% (66.5%-92.5%), respectively (AUC: 0.649 (0.549, 0.741)) which can more effectively identify PD-L1-negative patients. Other metabolic parameters are less effective than COV (AUC< 0.6). In addition, COV-defined metabolic heterogeneity outperformed other metabolic parameters in predicting PD-L1 expression (P = 0.049) and emerged as an independent predictor.
Conclusion
Metabolic heterogeneity, described by the COV of the primary lesion, is a marker for predicting PD-L1 expression in NSCLC patients. Therefore, the COV of the primary tumour may complement conventional imaging in providing immunohistochemical information before biopsy. Advances in knowledge COV of the primary tumour can predict PD-L1 expression, potentially complementing conventional imaging for immunohistochemical information prior to biopsy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- PET/CT Center, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China.
ORCID-Profile: Xiaoyi Duan
Förderung
- National High Performance medical Device Innovation Center Innovation Fund
Zitieren
APA
Chang, R., Luo, L., Shen, C., Zhang, W., & Duan, X. (2025). Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf034
Vancouver
Chang R, Luo L, Shen C, Zhang W, Duan X. Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity. British Journal of Radiology. 2025. doi:10.1093/bjr/tqaf034
BibTeX
@article{Chang2025,
author = {Chang, Ruxi and Luo, Liang and Shen, Cong and Zhang, Weishan and Duan, Xiaoyi},
title = {Using 18F-FDG PET/CT to predict programmed cell death ligand expression in non-small cell lung cancer via metabolic tumour heterogeneity},
journal = {British Journal of Radiology},
year = {2025},
doi = {10.1093/bjr/tqaf034}
}
EUVIMED